The survival graphs below illustrate outcomes of unrelated donor hematopoietic cell transplants (bone marrow, PBSC, or cord blood transplants — BMT) coordinated by the National Marrow Donor Program® (NMDP) for adult patients with non-Hodgkin lymphoma (NHL).
Figure 1 shows that there is no significant difference in five-year survival for adult patients (≥18 years of age) undergoing non-myeloablative transplantation for NHL regardless of stem cell source (log-rank p-value=0.255). Most NHL patients who receive an unrelated donor or cord blood transplant are transplanted at the time the disease recurs.
Figure 1.
Non-Hodgkin lymphoma: Survival of adult non-myeloablative transplant patients by stem cell source, 2000-2009. (NMDP data)
View larger version Download slide (PPT)
Figure 2.
Non-Hodgkin lymphoma: Survival of adult bone marrow transplant patients by disease histology, 2000-2009. (NMDP data)
View larger version Download slide (PPT)
Figure 3.
Non-Hodgkin lymphoma: Survival of adult PBSC transplant patients by disease histology, 2000-2009. (NMDP data)
View larger version Download slide (PPT)